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145 The efﬁcacy of the inhalatory treatment with tobramycin in
controlling Pseudomonas aeruginosa lung infection in patients
with cystic ﬁbrosis
S. Sciuca1, R. Eremciuc1. 1State University of Medicine and Pharmacy “Nicolae
Testemitanu”, Department of Pediatrics, Chisinau, Moldova, Republic of
Background: Pseudomonas aeruginosa lung infection in cystic ﬁbrosis (CF) leads
to a negative impact in disease evolution and enforces therapeutic programs for
controlling and eradication of this infection.
Objectives: The assessment of tobramycin inhaled therapy in patients with CF
associated with P. aeruginosa chronic lung infection.
Methods: The study includes 15 patients with CF associated with chronic airway
infection with P. aeruginosa. CF diagnosis was conﬁrmed through positive sweat
test and genetic testing of the CFTR mutations. The patients’ average age was
14.86±5.6 years (8−25 years). Tobramycin aerosol therapy (TOBI 300mg/5ml) was
performed in an alternating program (300mg ×2, 28 days 4−6 cycles). Respiratory
FVC and FEV1 indices were used for lung function monitoring.
Results: Before starting tobramycin treatment, all the patients showed de-
creased spirometric indices: FVC (63.66±1.64%) and FEV1 (59.8±1.46%). After
12 months of treatment, these indices improved to FVC 67.23±1.11%, FEV1
62.95±2.33%. Inhaled tobramycin treatment also determined a suppression of
P. aeruginosa infection in patients with CF. P. aeruginosa titres were 103−108 (mean
titre 6.31±0.11) before the treatment and decreased with 1−3 titres in 46.7% of
cases. P. aeruginosa infection was completely eradicated in 13.3% of cases.
Conclusion: Tobramycin aerosol therapy helps to control and eradicate P. aerugi-
nosa lung infection and improves respiratory function by increasing FVC and FEV1
spirometric indices.
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UK Pseudomonas serology (Ps Ab) use is sparse. The EPIC study suggests
raised Ps Ab (RPsA) in 1st/new growths of Pseudomonas aeruginosa (PA) predict
recurrent PA. Chronic PA is deﬁned as Ps Ab >2, recent PA Ps Ab >1 and
normal <1. Ps Ab levels have been used in our PA eradication protocol for
6 years. Ps Ab levels are taken annually, at 1st/new PA (post previous eradication)
(1st/newPA) and at 3 months of standard eradication (3 months colistin and 3 weeks
ciproﬂoxacin). RPsA children also receive TSI +/− iv antibiotics in the 2nd of
3 month regime. If Ps Ab remain raised at 3 months colistin is continued.
Objectives: To explore if RPsA predicted time to regrowth/development of
chronic PA.
Methods: Retrospective review of 1st/newPA growths (previous Ps Ab >1.1
excluded).
Outcomes: Time to PA re-growth and Leeds Criteria PA status over mean
3.5 yr follow-up (f/u).
Results: 54 children (27 male). Median age at 1st/newPA was 4.9 yr (IQR 1.7−8.9).
19 (35%) had RPsA. 13 received TSI +/− iv antibiotics. Time to PA regrowth: 1.36 yr
in RPsA vs 1.29 yr in not raised. At f/u 4/19 (21%) in RPsA had chronic PA vs
3/35 (9%) in not raised. Rates of complete eradication over 3.5 yr f/u were similar
7/19 (36%) vs 11/35 (31%) in not-raised group. Ps Ab rise was higher if developed
chronic PA: 1.21 vs 0.79 if intermittent and 0.74 if eradicated (p = 0.01).
Conclusion: We found no difference in time to PA re-growth if RPsA, maybe due
to the more aggressive attempts at eradication. Those going on to have chronic PA
infection had a signiﬁcantly greater initial rise in Ps Ab levels (>1.21). This may be
a useful tool to direct early aggressive attempts at eradication at 1st/new PA growth.
147 Causes of failure to eradicate Pseudomonas aeruginosa in
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Background: Respiratory infection with P. aeruginosa (PA) is a leading cause of
morbi-mortality in patients with Cystic ﬁbrosis (CF). It is associated with a more
rapid decline in pulmonary function, worsening nutritional status, more hospital
admissions and a shorter life expectancy. Although several protocols for eradication
of PA after the ﬁrst isolation are in use, the optimal antibiotic combination, dosages,
modes of delivery and duration of therapy remains unresolved. Still, 10−20% of
PA infections cannot be eradicated and become chronic infection; therefore, it is
imperative to understand what are the factors associated with failure to eradicate
PA in CF.
Aims: To analyze the rate of eradication failure of ﬁrst or new PA infection and to
identify clinical and laboratory factors that are associated with eradication failure.
Methods: Records of 130 CF patients treated at the Hadassah Medical Center and
in other 5 CF centers in Israel were reviewed. Demographic, clinical and laboratory
data collected over the last 7 years were retrospectively analyzed.
Results: Older age, pancreatic insufﬁciency status, less often visits to the CF center,
multi/pan-resistant PA, colonization of PA in the past, later age at diagnosis, air-
trapping in the CT scan, later age at CF diagnosis, and no-treatment with hypertonic
saline were identiﬁed as risk factors for eradication failure. After multivariate
analysis, the lasts two issues were the more strongly associated with failure to
eradicate PA.
Conclusions: Early diagnosis and appropriate therapy is required in order to
augment the rate of efﬁciently eradication of PA in patients with CF.
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Objectives: Pseudomonas aeruginosa is the most commonly isolated pathogen from
the sputum of adults with cystic ﬁbrosis (CF). The Midlands-1 clone is the most
commonly recovered genotype in our local patient population, affecting one-third
of P. aeruginosa positive patients. Although Midlands-1 is readily identiﬁed by
conventional typing schemes, such assays lack the discriminatory power to identify
potential transmission events.
Methods: We sequenced the complete genomes of >150 isolates of Midlands-1
isolates from: (i) P. aeruginosa positive patients attending the West Midlands Adult
CF Centre in a prospective survey, (ii) all Midlands-1 isolates collected over 5 years
from the Liverpool Heart and Chest Hospital and (iii) a national collection of
isolates from Public Health England over 15 years.
Results: Whole-genome sequencing (WGS) and phylogenetic analysis using core
genome single nucleotide polymorphisms conﬁrmed Midlands-1 has a clonal pop-
ulation structure. Evidence for direct transmission of P. aeruginosa was suggested
from phylogenetic reconstructions, with diversity seen in isolates from three patients
fully contained within the diversity seen in a single other patient. Epidemiological
data suggested transmission from this patient to others was possible during inpatient
stays. Long branches on the tree were associated with a hypermutator phenotype
and increased levels of antibiotic resistance.
Conclusions: It is likely that new acquisitions of P. aeruginosa may result from
transmission between patients. WGS is a useful and increasingly affordable tool
which may be used to enhance surveillance and infection control of P. aeruginosa
in CF patients.
